Cargando…

571. A Report of the Postmarketing Spontaneous Safety Data over 24 Years for GSK’s Measles-Mumps-Rubella (MMR) Vaccine

BACKGROUND: GSK’s measles-mumps-rubella (MMR) vaccine is indicated for active immunization of individuals aged 12 months and older against these 3 serious illnesses. It is licensed in > 100 countries worldwide not including the US. In clinical trials, it elicited robust immune responses in childr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, Tina, Casabona, Giacomo, Abu-Elyazeed, Remon, Vetter, Volker, Hergibo, Fanny
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166264/ http://dx.doi.org/10.1093/ofid/ofac492.624

Ejemplares similares

Clinical trials show similar safety outcomes including febrile convulsion rates for GSK’s and Merck’s measles-mumps-rubella (MMR) vaccines
por: Habib, Md Ahsan, et al.
Publicado: (2023)

Correction to: 571. A Report of the Postmarketing Spontaneous Safety Data over 24 Years for GSK’s Measles-Mumps-Rubella (MMR) Vaccine
Publicado: (2023)

Response to Measles, Mumps and Rubella (MMR) Vaccine in Transfusion-Dependent Patients
por: Casale, Maddalena, et al.
Publicado: (2021)

Improving health literacy with mumps, measles and rubella (MMR) vaccination: comparison of the readability of MMR patient-facing literature and MMR scientific abstracts
por: Downey, Tina, et al.
Publicado: (2022)

Analysis of Measles-Mumps-Rubella (MMR) Titers of Recovered COVID-19 Patients
por: Gold, Jeffrey E., et al.
Publicado: (2020)

Are Measles-Mumps-Rubella (MMR) Antibodies Friends or Foes for Covid-19 Disease?
por: Salamony, Azza, et al.
Publicado: (2023)

Anticancer Activity of Measles–Mumps–Rubella MMR Vaccine Viruses against Glioblastoma
por: Khalid, Zumama, et al.
Publicado: (2023)

An Economic Analysis of Mumps Vaccination in Fiji: Static Model Simulation of Routine Measles–Mumps–Rubella (MMR) Vaccination Instead of Current Measles–Rubella (MR) Vaccination
por: Oh, Chunghyeon, et al.
Publicado: (2022)

Seroprevalence of Antibodies to Measles, Mumps, and Rubella among Thai Population: Evaluation of Measles/MMR Immunization Programme
por: Tharmaphornpilas, Piyanit, et al.
Publicado: (2009)

Missed Opportunities for Measles, Mumps, and Rubella (MMR) Immunization in Mesoamerica: Potential Impact on Coverage and Days at Risk
por: Mokdad, Ali H., et al.
Publicado: (2015)

Measles, Mumps, and Rubella Antibody: Patterns of Persistence and Rate of Decline Following the Second Dose of the MMR Vaccine
por: Seagle, Emma, et al.
Publicado: (2017)

Relationship Between Media Coverage and Measles-Mumps-Rubella (MMR) Vaccination Uptake in Denmark: Retrospective Study
por: Hansen, Niels Dalum, et al.
Publicado: (2019)

2763. Uptake and Safety of Measles-Mumps-Rubella (MMR) Vaccine in Adolescents and Adults in the Vaccine Safety Datalink
por: Hanson, Kayla E, et al.
Publicado: (2019)

A Study to Evaluate the Role of Intradermal and Intralesional Measles, Mumps, Rubella (MMR) Vaccine in Treatment of Common Warts
por: Gupta, Pragya, et al.
Publicado: (2020)

Lessons Learned from Publicizing and Retracting an Erroneous Hypothesis on the Mumps, Measles, Rubella (MMR) Vaccination with Unethical Implications
por: Khan, Hiba, et al.
Publicado: (2021)

Auto-immune thrombocytopenia after Measles Mumps Rubella MMR vaccination: molecular mimicry of measles virus phosphoprotein with platelet gpIIb
por: Tran, Guy Mong Ky, et al.
Publicado: (2010)

Difficulties in Eliminating Measles and Controlling Rubella and Mumps: A Cross-Sectional Study of a First Measles and Rubella Vaccination and a Second Measles, Mumps, and Rubella Vaccination
por: Wang, Zhifang, et al.
Publicado: (2014)

Does Measles, Mumps, and Rubella (MMR) Vaccination Protect against COVID-19 Outcomes: A Nationwide Cohort Study
por: Kolla, Epiphane, et al.
Publicado: (2022)

Characterisation of measles after the introduction of the combined measles-mumps-rubella (MMR) vaccine in 2004 with focus on the laboratory data, 2016 to 2019 outbreak, Romania
por: Lazar, Mihaela, et al.
Publicado: (2019)

Addressing issues of vaccination literacy and psychological empowerment in the measles-mumps-rubella (MMR) vaccination decision-making: a qualitative study
por: Fadda, Marta, et al.
Publicado: (2015)

Non-specific effects of measles, mumps, and rubella (MMR) vaccination in high income setting: population based cohort study in the Netherlands
por: Tielemans, Susanne M A J, et al.
Publicado: (2017)

Municipality-level measles, mumps, and rubella (MMR) vaccine coverage and deprivation in Brazil: A nationwide ecological study, 2006 to 2020
por: Godin, Audrey, et al.
Publicado: (2023)

Measles, Mumps, Rubella serology in juvenile idiopathic arthritis
por: Heijstek, MW, et al.
Publicado: (2008)

Is it time to reconsider measles, mumps, and rubella immunisation strategies?
por: Boccalini, Sara, et al.
Publicado: (2021)

Measles-Mumps-Rubella Vaccine and COVID-19 Relationship
por: Özdemir, Öner
Publicado: (2020)

Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A phase III, randomized study
por: Abu-Elyazeed, Remon, et al.
Publicado: (2018)

2467. Timeliness of Childhood Vaccination With the Combination Measles–Mumps–Rubella–Varicella Vaccine vs. the Separate Measles–Mumps–Rubella and Varicella Vaccines in the United States
por: Wolfson, Lara, et al.
Publicado: (2018)

Resurgence risk for measles, mumps and rubella in France in 2018 and 2020
por: Béraud, Guillaume, et al.
Publicado: (2018)

Utility of serological screening for measles, mumps and rubella in immunocompromised patients
por: Sticchi, L, et al.
Publicado: (2019)

Inadequate Measles, Mumps, Rubella, and Varicella Immunity Among Employees
por: Ezeji-Okoye, Stephen, et al.
Publicado: (2021)

Knowledge and Practice of Parents Towards Measles, Mumps and Rubella Vaccination
por: Hussein, Siti Zuhaida, et al.
Publicado: (2022)

1077 Adverse events following measles, mumps, and rubella (MMR) vaccine in adults reported to the Vaccine Adverse Event Reporting System, 2003-2013
por: Sukumaran, Lakshmi, et al.
Publicado: (2014)

1339 Measles and Mumps Antibody Response in Young Adults after a Third Dose of Measles-Mumps-Rubella Vaccine
por: Fiebelkorn, Amy Parker, et al.
Publicado: (2014)

Attitudinal and Demographic Predictors of Measles-Mumps-Rubella Vaccine (MMR) Uptake during the UK Catch-Up Campaign 2008–09: Cross-Sectional Survey
por: Brown, Katrina, et al.
Publicado: (2011)

Comparative Study of Efficacy of Intralesional Purified Protein Derivative (PPD) Versus Intralesional Measles, Mumps, and Rubella (MMR) Vaccine in Management of Multiple Viral Warts
por: Bhalala, Krishna B, et al.
Publicado: (2021)

Partial third nerve palsy after Measles Mumps Rubella vaccination
por: Manzotti, Francesca, et al.
Publicado: (2010)

Efficacy of intralesional injection of mumps-measles-rubella vaccine in patients with wart
por: Zamanian, Abbas, et al.
Publicado: (2014)

Perspectives on the Measles, Mumps and Rubella Vaccination among Somali Mothers in Stockholm
por: Jama, Asha, et al.
Publicado: (2018)

Reply to Özdemir, “Measles-Mumps-Rubella Vaccine and COVID-19 Relationship”
por: Fidel, Paul L., et al.
Publicado: (2020)

Measles-mumps-and-rubella-virus-vaccine: Aseptic meningitis: case report
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hgsnle39on6q30ljgj6pno3rh9